找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: NETWORKING 2004: Networking Technologies, Services, and Protocols; Performance of Computer and Commu; Networking Technolog Nikolas Mitrou,K

[復(fù)制鏈接]
樓主: 弄混
31#
發(fā)表于 2025-3-27 00:22:49 | 只看該作者
32#
發(fā)表于 2025-3-27 01:31:38 | 只看該作者
Uday Mohan,Kevin C. Almeroth,Elizabeth M. Belding-Royercellent properties facilitate subsequent interactions of the biomolecules and their interacting partners during the screening process. We envision that the immobilization strategy described here can find useful applications in many other microarray related studies.
33#
發(fā)表于 2025-3-27 06:36:54 | 只看該作者
34#
發(fā)表于 2025-3-27 11:35:30 | 只看該作者
35#
發(fā)表于 2025-3-27 15:47:56 | 只看該作者
36#
發(fā)表于 2025-3-27 20:57:49 | 只看該作者
Anirban Chakrabarti,Govindarasu Manimaranto as a scoring function. In order to be successful as a virtual screening tool, a docking program must be able to find optimum docking solutions for active molecules in accordance with experiment, it should be able to separate active compounds from inactive ones, and it should use no more than 2–3
37#
發(fā)表于 2025-3-28 01:15:17 | 只看該作者
Moonseong Kim,Young-Cheol Bang,Hyunseung Chooto as a scoring function. In order to be successful as a virtual screening tool, a docking program must be able to find optimum docking solutions for active molecules in accordance with experiment, it should be able to separate active compounds from inactive ones, and it should use no more than 2–3
38#
發(fā)表于 2025-3-28 02:39:12 | 只看該作者
Hwangjun Song,Dong Sup Leestic reduction of the tumor bulk within a few hours after administration. Venetoclax was approved by the FDA and EMA in 2016 for patients with previously treated CLL with del(17p13) and patients failing B cell receptor signaling inhibitors (EMA only), on the basis of a single-arm phase II trial demo
39#
發(fā)表于 2025-3-28 06:36:31 | 只看該作者
Bernardo A. M. Villela,Otto Carlos M. B. DuarteOlaparib is already approved for the treatment of patients with recurrent ovarian cancer and a BRCA mutation, and it has been shown to provide clinically meaningful benefits among such patients. It has also shown promising activity in patients with metastatic breast or prostate cancer and a germline
40#
發(fā)表于 2025-3-28 10:38:37 | 只看該作者
0302-9743 fortunate to attract very high interest among the c- munity, and the conference received 539 submissions from 44 countries in all ?ve continents. These ?gures 978-3-540-21959-0978-3-540-24693-0Series ISSN 0302-9743 Series E-ISSN 1611-3349
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-19 14:26
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
射洪县| 万州区| 仁寿县| 龙山县| 扶风县| 普定县| 监利县| 克什克腾旗| 开鲁县| 梁河县| 翁源县| 蕉岭县| 即墨市| 康平县| 和硕县| 绥化市| 从江县| 襄垣县| 云梦县| 湄潭县| 怀来县| 会泽县| 汝阳县| 石屏县| 门源| 怀远县| 太保市| 襄樊市| 静安区| 武山县| 赤壁市| 桦南县| 府谷县| 灵石县| 石台县| 宕昌县| 中江县| 奈曼旗| 富顺县| 天镇县| 平远县|